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Abstract
Background: There has been debate about the cost-effectiveness of photodynamic therapy
(PDT), a treatment for neovascular age-related macular degeneration. We have been monitoring
trends for the provision of PDT in the UK National Health Service. The fourth annual 'tracker'
survey took place as definitive National Institute for Clinical Excellence (NICE) guidance was issued.
We assessed trends in PDT provision up to the point of release of the NICE guidance and identified
likely sources of pressure on ophthalmologists to provide PDT.
Methods: National postal questionnaire survey of clinicians with potential responsibility for PDT
provision. The survey explored reported local provision, beliefs about the effectiveness of PDT and
what sources of opinion might influence attitudes towards providing PDT.
Results: The response rate was 73% (111/150). Almost half of the surveyed ophthalmology units
routinely provided PDT, as part of a trend of steady growth in provision. The proportion of
respondents who believed that further proof of effectiveness was required has also declined
despite the absence of any new substantial evidence. Attitudes towards providing PDT were
positive, on average, and were more strongly associated with perceived social pressure from local
colleagues than from other sources. Local colleagues were seen as being most approving of PDT.
Conclusion: Those responsible for implementing the NICE guidance need to address
ophthalmologists' beliefs about the evidence of effectiveness for PDT and draw upon supportive
local individuals or networks to enhance the credibility of the guidance.
Background
Age related macular degeneration (ARMD) is the com-
monest cause of severe loss of central vision in people
aged over 50 in the Western world [1] and accounts for
almost 50% of those registered as blind or partially
sighted in the UK [2]. One form of the disease, neovascu-
lar ARMD, is more aggressive and accounts for up to 15%
of cases [1]. Evidence from two randomised trials indi-
cates that photodynamic therapy (PDT), administered
five to six times over a two year period, reduces the relative
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risk of losing three or more lines of visual acuity over two
years [3,4]. In particular, a subgroup analysis has shown a
statistically significant benefit in the prevention of visual
loss in people with wholly or predominantly classic
choroidal neovascularisation (CNV). These findings con-
tributed to pressure upon the UK National Health Service
(NHS) from both patient and professional groups to
make this therapy routinely available [5,6]. However, sys-
tematic reviews have highlighted reservations with respect
to the reliance placed on the subgroup analysis [7-9].
Concern about the cost-effectiveness of PDT [10]
prompted the National Institute for Clinical Excellence
(NICE) to undertake a technology appraisal of PDT. Yet,
during the protracted course of the technology appraisal
and subsequent appeals, there was evidence that ophthal-
mology units were establishing services or referring
patients for PDT.
When it was released in September 2003, the NICE guid-
ance specified that only the subgroup of patients with
100% classic CNV should be eligible for PDT. Ideally,
strategies to promote effective practice should be tailored
according to identified local needs and barriers [11]. The
rate of uptake of the NICE guidance may be influenced by
several factors, such as ophthalmologists' perceptions of
treatment benefit and time required to establish new serv-
ices. Groups such as local colleagues or professional bod-
ies may themselves influence clinicians' beliefs about
treatment benefit. Hence the promotion of the NICE guid-
ance may be more effective if it takes account of such pro-
fessional norms.
We have been conducting a series of 'tracker' surveys to
follow trends in the uptake of PDT. Our fourth survey,
coincidently conducted as the final NICE guidance was
being released [12], addressed whether provision of PDT
had continued to expand despite the absence of the guid-
ance and whether perceived professional norms represent
a barrier to its implementation.
Methods
Questionnaire design and administration were similar to
those used in the previous three surveys [13-15]. We
sought information about local treatment and referral
policies for neovascular ARMD and the threshold of clin-
ical benefit considered sufficient to justify the use of PDT.
Benefit was rated on the basis of the number of patients
that the respondent would be willing to treat to prevent
the loss of three lines of visual acuity for two years for one
patient at a given fixed cost of treatment of £8000 per
patient (known as the number needed to treat (NNT)).
This cost was estimated from the TAP study treatment pro-
tocol [1]. Six options for the NNTs were presented, four
based upon the point estimate of effect and upper and
lower limits of the 95% confidence intervals reported in
the Cochrane Review [7], and two further categories of 1
in 50 and 1 in 100 for comparative purposes.
We used two constructs from the Theory of Planned
Behaviour [16] to measure attitudes and subjective norms
(which we shall now refer to as perceived social pressure)
concerning the use of PDT. The questionnaire incorpo-
rated previously recommended scales and items to meas-
ure attitudes and perceived social pressure for a specific
action: the treatment of patients with predominantly
(more than 50%) classic sub-foveal CNV using photody-
namic therapy [17]. Attitudes towards this use of PDT
were measured using 1–7 Likert scales for four items (ben-
eficial/harmful to patients; an excellent/poor use of
resources; clinically/not clinically effective; good/bad
practice). Ophthalmologists might feel under pressure
from different groups. Four perceived social pressure
items asked how much each of the following would
approve or disapprove of the use of PDT: local colleagues,
the Royal College of Ophthalmologists, NICE, and other
ophthalmologists. Local colleagues might encompass
both (mainly) ophthalmologists and others; whilst 'other
ophthalmologists' would refer to any others encountered
via formal and informal networks. The Royal College of
Ophthalmologists and NICE refer to (perceived) official
policy from each organisation.
Following pre-testing of the additional theory-based
items, the questionnaire was posted to all clinical direc-
tors or lead consultants in NHS ophthalmology units
within the UK in the autumn of 2003. The units were
identified using the Royal College of Ophthalmologists'
database. One reminder was sent to non-respondents.
Changes in service provision and beliefs were analysed
using the χ2-test, and the normal z-test to compare two
proportions. P values are presented. Associations between
attitudes (the combined means of the four items) and
each of the four perceived social pressure items were
measured using multiple regression analysis. Differences
between levels of perceived approval from the four poten-
tial sources of social pressure were tested using the
repeated measures ANOVA.
Results
Out of 150 questionnaires, 111 (73%) were returned
completed, a slightly lower response rate than those for
the previous three surveys (82%, 79% and 80% respec-
tively). No variations in response rate were detected by
health region either overall or in the individual surveys.
The proportion of units reporting routine provision of
PDT for patients with more than 50% classic sub-foveal
CNV significantly increased over four years from 8.5% to
41% (p < 0.001), making this the most common reported
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policy for the first time. The proportion of units referring
or treating no patients fell from 35% to 5% (Figure 1, p <
0.001).
There was a significant change in beliefs of what consti-
tuted a worthwhile clinical benefit over 2000–1 (p =
0.01), but no significant change was detected over 2001–
2 (p = 0.97), or 2002–3 (p = 0.13) (Table 1) The propor-
tion of respondents requiring further evidence before sup-
porting the use of PDT fell from 33% to 11% over the four
years. Lower thresholds supporting the use of PDT were
associated with greater reported provision over the four
surveys (χ2 = 20.4, df = 8, p = 0.01; χ2 = 25.2, df = 8, p =
0.003; χ2 = 21.2, df = 8, p = 0.007, χ2 = 17.0, df = 8, p =
0.03 respectively).
The mean score for attitude was 4.86 (sd = 1.07), based on
the 1–7 scale where higher scores represented more posi-
tive attitudes towards PDT for the treatment of patients
with predominantly (more than 50%) classic sub-foveal
CNV. Internal consistency was acceptable for the four atti-
tude items (Cronbach's α = 0.69). The mean scores for
perceived social pressure ranged from 2.86 for local col-
leagues to 3.82 for NICE, where lower scores represent
greater levels of perceived approval (Table 2). A repeated
measures ANOVA showed that perceived approval dif-
Trends in the reported provision of photodynamic therapy over 2000–2003Figure 1
Trends in the reported provision of photodynamic therapy over 2000–2003.

















Routine provision for patients > 50% classic CNV Individual case decided upon merits
Referral to the private sector No patients to be referred or treated
Table 1: Beliefs about clinical benefit and evidence of effectiveness over 2000–2003.
Threshold of clinical benefit that would make offering PDT as a treatment worthwhile Survey year
2000 2001 2002 2003
To prevent the loss of 3 lines of visual acuity over 2 years At least In 1 person for every 7 
treated
22 (19%) 31 (27%) 30 (28%) 36 (37%)
In 1 person for every 4 treated 35 (30%) 37 (32%) 38 (35%) 34 (35%)
In 1 person for every 2 treated 21 (18%) 27 (23%) 20 (19%) 16 (17%)
Further evidence of effectiveness required 39 (33%) 20 (19%) 20 (17%) 11 (11%)
Total 117 108 115 97
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fered significantly as a function of the source of perceived
social pressure (F(3,91) = 15.58, p < 0.001). NICE was
seen as most disapproving of PDT use for the given indi-
cation; this was significantly different from scores for the
other three sources of pressure (p < 0.001).
In the multiple regression analysis, scores for the four
sources of social pressure significantly predicted attitude
scores, R = 0.51, F(4,93) = 7.67, p < 0.001 (Table 3).
Inspection of individual standardised regression coeffi-
cients (beta weights) showed that only perceived social
pressure from local colleagues was a significant predictor
of attitudes (p < 0.01).
Discussion
By the time that the NICE guidance was released, almost
half of the surveyed ophthalmology units were already
routinely providing PDT. The proportion of respondents
who believed that further proof of effectiveness was
required has also declined despite the absence of any new
substantial evidence. Attitudes towards providing PDT
were positive, on average, and were more strongly associ-
ated with perceived social pressure from local colleagues
than from other sources. Local colleagues were seen as
being most approving of PDT.
There were several limitations to our methods. First, sur-
vey respondents may have held stronger views, or other-
wise, about the merits of PDT compared with non-
respondents. Second, additional variation in our findings
over time may have been introduced by differences in
respondents over each survey, although a sub-analysis
provision of PDT for the units that responded to all four
surveys (n= 76 (51%)) indicated similar findings as for
the overall survey. Third, reported policies may differ
from those used in practice. Fourth, the issue of NICE
guidance around the time of the last survey may have
altered responses. This seems unlikely to be a major fac-
tor, given the time taken to establish new services or refer-
ral policies. We also found no significant difference in
attitudes towards PDT between those respondents who
said they had read the NICE guidance and those who had
not. Fifth, it would be wrong to assume the direction of
causality was such that perceived social pressure influ-
enced attitudes; more positive attitudes towards PDT
might have preceded perceptions about which source
approved or disapproved of PDT use. Finally, we enquired
only about a limited number of sources of social pressure.
Other sources might have included patients or the com-
mercial sector, although social desirability bias might
have led to an underestimation of effects of the latter.
In a classic case of 'technology creep' [18], PDT has
become an established treatment in the NHS prior to
national guidance and in the absence of new supporting
evidence. This raises the question as to whether the rou-
tine application of new health technologies should be
subject to a strict national moratorium. Proponents of
PDT would argue that such a moratorium would stifle
local service innovation, especially in light of the time
taken to develop and issue final national guidance. How-
ever, we have previously suggested that the long time scale
required to issue more controversial technology assess-
ments may work in favour of the advocates of new tech-
nologies by forcing the hand of policy-makers [15].
There is also a risk of 'indication creep', whereby the use
of an intervention expands beyond its recommended
indication and results in less cost-effective use of health
care resources. The NICE guidance specifies that only
patients with 100% – as opposed to at least 50% – classic
CNV should be eligible for PDT. The uptake of this guid-
Table 2: Mean perceived social pressure for the treatment of 
patients with predominantly (more than 50%) classic sub-foveal 
CNV using photodynamic therapy where possible scores range 
from 1 (strongly approve) to 7 (strongly disapprove).
Source of perceived social pressure Mean Standard 
deviation
Local colleagues 2.86 1.34
Royal College of Ophthalmologists 3.01 1.23
National Institute for Clinical Excellence (NICE) 3.82 1.49
Other ophthalmologists 3.00 1.41
Table 3: Multiple regression of scores for perceived social pressure on attitude scores. (Beta weights are negative because perceived 
social pressure and attitude scores were scored in opposite directions.)
Dependent variable Independent variables β R R2 Adjusted R2
Attitude concerning the use of PDT Social pressure from local colleagues -0.38**
Social pressure from the RCO -0.03
Social pressure from NICE -0.05
Social pressure from other ophthalmologists -0.14
0.51*** 0.26 0.22
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ance will partly depend upon the perceived credibility of
the messenger. Our findings suggest that ophthalmolo-
gists are currently more likely to be influenced by local
colleagues than by NICE, thereby posing a potential threat
to consistent adherence to the guidance.
All of this means that those responsible for implementing
the NICE guidance need to address ophthalmologists'
beliefs about the evidence of effectiveness for PDT and
draw upon supportive local individuals or networks to
enhance the credibility of the guidance.
The implementation of national guidance requires moni-
toring. We plan to conduct one further survey to audit the
reported uptake of the NICE guidance and measure the
extent of any 'indication-creep'.
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